|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rustgi AK and El-Serag HB: Esophageal
carcinoma. N Engl J Med. 371:2499–2509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steyerberg EW, Neville B, Weeks JC and
Earle CC: Referral patterns, treatment choices, and outcomes in
locoregional esophageal cancer: A population-based analysis of
elderly patients. J Clin Oncol. 25:2389–2396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kinugasa S, Tachibana M, Yoshimura H, Dhar
DK, Shibakita M, Ohno S, Kubota H, Masunaga R and Nagasue N:
Esophageal resection in elderly esophageal carcinoma patients:
Improvement in postoperative complications. Ann Thorac Surg.
71:414–418. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferry DR, Anderson M, Beddard K, et al: A
phase II study of gefitinib monotherapy in advanced esophageal
adenocarcinoma: Evidence of gene expression, cellular, and clinical
response. Clin Cancer Res. 13:5869–5875. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rao S, Starling N, Cunningham D, et al:
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX)
compared with epirubicin, cisplatin and capecitabine alone as
first-line treatment in patients with advanced oesophago-gastric
cancer: A randomised, multicentre open-label phase II study. Ann
Oncol. 21:2213–2219. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT
and Wang H: Lapatinib, a dual inhibitor of EGFR and HER2, has
synergistic effects with 5-fluorouracil on esophageal carcinoma.
Oncol Rep. 27:1639–1645. 2012.PubMed/NCBI
|
|
9
|
Waddell T, Chau I, Cunningham D, et al:
Epirubicin, oxaliplatin, and capecitabine with or without
panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramakrishnan MS, Eswaraiah A, Crombet T,
Piedra P, Saurez G, Iyer H and Arvind AS: Nimotuzumab, a promising
therapeutic monoclonal for treatment of tumors of epithelial
origin. MAbs. 1:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang J, E M, Wu G, et al: Nimotuzumab
combined with radiotherapy for esophageal cancer: Preliminary study
of a phase II clinical trial. Onco Targets Ther. 6:1589–1596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma NY, Cai XW, Fu XL, Li Y, Zhou XY, Wu
XH, Hu XC, Fan M, Xiang JQ, Zhang YW, et al: Safety and efficacy of
nimotuzumab in combination with radiotherapy for patients with
squamous cell carcinoma of the esophagus. Int J Clin Oncol.
19:297–302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Takeuchi S, Ohtsu A, Doi T, Kojima T,
Minashi K, Mera K, Yano T, Tahara M, Muto M and Nihei K: A
retrospective study of definitive chemoradiotherapy for elderly
patients with esophageal cancer. Am J Clin Oncol. 30:607–611. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhai Y, Hui ZG, Wang JB, et al: Concurrent
erlotinib and radiotherapy for elderly squamous cell esophageal
carcinoma: Results of a pilot study. Int J Radiat Oncol.
81:(Suppl). S3132011. View Article : Google Scholar
|
|
15
|
Iyer R, Chhatrala R, Shefter T, et al:
Erlotinib and radiation therapy for elderly patients with
esophageal cancer - clinical and correlative results from a
prospective multicenter phase 2 trial. Oncology. 85:53–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rice TW, Blackstone EH and Rusch VW: 7th
edition of the AJCC Cancer Staging Manual: Esophagus and
esophagogastric junction. Ann Surg Oncol. 17:1721–1724. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schröder W, Baldus SE, Mönig SP, Beckurts
TK, Dienes HP and Hölscher AH: Lymph node staging of esophageal
squamous cell carcinoma in patients with and without neoadjuvant
radiochemotherapy: Histomorphologic analysis. World J Surg.
26:584–587. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gietema JA, de Vries EG, Sleijfer DT,
Willemse PH, Guchelaar HJ, Uges DR, Aulenbacher P, Voegeli R and
Mulder NH: A phase I study of
1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466;
lobaplatin) administered daily for 5 days. Br J Cancer. 67:396–401.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Crombet T, Osorio M, Cruz T, Roca C, del
Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J,
Renginfo E, et al: Use of the humanized anti-epidermal growth
factor receptor monoclonal antibody h-R3 in combination with
radiotherapy in the treatment of locally advanced head and neck
cancer patients. J Clin Oncol. 22:1646–1654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Satoh T, Lee KH, Rha SY, et al: Randomized
phase II trial of nimotuzumab plus irinotecan versus irinotecan
alone as second-line therapy for patients with advanced gastric
cancer. Gastric cancer. Sep 5–2014.(Epub ahead of print).
View Article : Google Scholar
|
|
21
|
Li QQ, Liu MZ, Hu YH, Liu H, He ZY and Lin
HX: Definitive concomitant chemoradiotherapy with docetaxel and
cisplatin in squamous esophageal carcinoma. Dis Esophagus.
23:253–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gagliardi G, Constine LS, Moiseenko V,
Correa C, Pierce LJ, Allen AM and Marks LB: Radiation dose-volume
effects in the heart. Int J Radiat Oncol Biol Phys. 76:(Sul 3).
S77–S85. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marks LB, Bentzen SM, Deasy JO, Kong FM,
Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV,
Timmerman RD, et al: Radiation dose-volume effects in the lung. Int
J Radiat Oncol Biol Phys. 76:(Sul 3). S70–S76. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirkpatrick JP, van der Kogel AJ and
Schultheiss TE: Radiation dose-volume effects in the spinal cord.
Int J Radiat Oncol Biol Phys. 76:(Sul 3). S42–S49. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R and Coleman CN:
CTCAE v3.0: Development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ku GY and Ilson DH: Esophagogastric
cancer: Targeted agents. Cancer Treat Rev. 36:235–248. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kordes S, Cats A, Meijer SL and van
Laarhoven HW: Targeted therapy for advanced esophagogastric
adenocarcinoma. Crit Rev Oncol Hematol. 90:68–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Xi M, Zhao L, Shen JX, Li QQ, He
LR, Liu SL and Liu MZ: Is there a benefit in receiving concurrent
chemoradiotherapy for elderly patients with inoperable thoracic
esophageal squamous cell carcinoma? PLoS One. 9:e1052702014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xing L, Liang Y, Zhang J, et al:
Definitive chemoradiotherapy with capecitabine and cisplatin for
elder patients with locally advanced squamous cell esophageal
cancer. J Cancer Res Clin Oncol. 140:867–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Richards D, Kocs DM, Spira AI, David
McCollum A, Diab S, Hecker LI, Cohn A, Zhan F and Asmar L: Results
of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with
metastatic gastric and/or gastroesophageal junction adenocarcinoma:
Results of a randomised phase 2 study. Eur J Cancer. 49:2823–2831.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pinto C, Di Fabio F, Siena S, et al: Phase
II study of cetuximab in combination with FOLFIRI in patients with
untreated advanced gastric or gastroesophageal junction
adenocarcinoma (FOLCETUX study). Ann Oncol. 18:510–517. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pérez-Soler R, Delord JP, Halpern A, Kelly
K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulières
D, et al: HER1/EGFR inhibitor-associated rash: Future directions
for management and investigation outcomes from the HER1/EGFR
inhibitor rash management forum. Oncologist. 10:345–356. 2005.
View Article : Google Scholar : PubMed/NCBI
|
